📊 ENTA Key Takeaways
Is ENTA a Good Investment? Thesis Analysis
Enanta Pharmaceuticals faces severe operational challenges with persistent unprofitability, negative free cash flow of -$11.8M, and deteriorating fundamentals despite maintaining a strong balance sheet. The company is burning cash at an unsustainable rate while revenues declined 3.4% YoY, indicating a lack of sustainable business model or revenue growth to offset operating losses.
Why Buy ENTA? Key Strengths
- Strong liquidity position with $37.4M cash and 4.44x current ratio providing runway for operations
- Low financial leverage with 0.02x debt-to-equity ratio and minimal long-term debt of $2.0M
- Reasonable asset base of $329.5M with stockholders' equity of $126.6M
ENTA Investment Risks to Consider
- Severe and deepening operational losses with -64.1% net margin and -60.5% operating margin
- Negative free cash flow of -$11.8M indicates company is consuming cash to fund operations, with only ~3.2 years of runway at current burn rate
- Revenue decline of 3.4% YoY combined with inability to achieve profitability suggests product portfolio challenges and lack of commercial traction
- Negative interest coverage ratio of -1.3x indicates inability to service debt from operations
Key Metrics to Watch
- Operating cash flow trend and runway sustainability
- Revenue stabilization and growth trajectory by product line
- Path to profitability and timeline to positive operating income
- Cash burn rate and total cash depletion timeline
- Pipeline advancement and clinical trial progress for late-stage candidates
ENTA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.44x current ratio provides a solid financial cushion.
ENTA Profitability Ratios
ENTA vs Healthcare Sector
How ENANTA PHARMACEUTICALS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENTA Overvalued or Undervalued?
Based on fundamental analysis, ENANTA PHARMACEUTICALS INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENTA Balance Sheet & Liquidity
ENTA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ENANTA PHARMACEUTICALS INC's revenue has declined by 61% over the 5-year period, indicating business contraction. The most recent EPS of $-6.38 indicates the company is currently unprofitable.
ENTA Growth Metrics (YoY)
ENTA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.0M | -$11.9M | $-0.42 |
| Q3 2025 | $18.0M | -$18.3M | $-0.85 |
| Q2 2025 | $14.9M | -$22.3M | $-1.06 |
| Q3 2024 | $18.0M | -$22.7M | $-1.07 |
| Q2 2024 | $17.1M | -$29.0M | $-1.47 |
| Q1 2024 | $17.0M | -$22.3M | $-1.05 |
| Q3 2023 | $18.9M | -$29.0M | $-1.53 |
| Q2 2023 | $17.8M | -$29.0M | $-1.63 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ENTA Capital Allocation
ENTA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ENANTA PHARMACEUTICALS INC (CIK: 0001177648)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENTA
What is the AI rating for ENTA?
ENANTA PHARMACEUTICALS INC (ENTA) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENTA's key strengths?
Claude: Strong liquidity position with $37.4M cash and 4.44x current ratio providing runway for operations. Low financial leverage with 0.02x debt-to-equity ratio and minimal long-term debt of $2.0M.
What are the risks of investing in ENTA?
Claude: Severe and deepening operational losses with -64.1% net margin and -60.5% operating margin. Negative free cash flow of -$11.8M indicates company is consuming cash to fund operations, with only ~3.2 years of runway at current burn rate.
What is ENTA's revenue and growth?
ENANTA PHARMACEUTICALS INC reported revenue of $18.6M.
Does ENTA pay dividends?
ENANTA PHARMACEUTICALS INC does not currently pay dividends.
Where can I find ENTA SEC filings?
Official SEC filings for ENANTA PHARMACEUTICALS INC (CIK: 0001177648) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENTA's EPS?
ENANTA PHARMACEUTICALS INC has a diluted EPS of $-0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENTA a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, ENANTA PHARMACEUTICALS INC has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENTA stock overvalued or undervalued?
Valuation metrics for ENTA: ROE of -9.4% (sector avg: 15%), net margin of -64.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENTA stock in 2026?
Our dual AI analysis gives ENANTA PHARMACEUTICALS INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENTA's free cash flow?
ENANTA PHARMACEUTICALS INC's operating cash flow is $-11.7M, with capital expenditures of $143.0K. FCF margin is -63.6%.
How does ENTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -64.1% (avg: 12%), ROE -9.4% (avg: 15%), current ratio 4.44 (avg: 2).